In the companion to this commentary, Marar et al1 present a clinical review on cardiotoxicities of cellular therapies and provide a framework for pre-, peri-, and post-treatment cardiac assessment to minimize cardiac comorbidity. Since the first reports of cardiotoxicity from anthracyclines in the 1970s,2 collateral damage to the cardiovascular system from cancer therapy has become a topic of interest. This interest has only been heightened with the advent of new cancer therapies that have improved cancer survival, making short- and long-term cardiovascular complications incredibly relevant to morbidity and mortality from cancer. Since the landmark approval of cellular therapy in 2017,3 the success of engineering a patient's own immune system to target tumor-specific antigens is a marvel of precision medicine. However, as is true in diseases where life-saving treatments are rapidly emerging, the path toward optimal and sustained outcomes includes constant vigilance for clinical safety. Early engineered T-cell experiences suggest potential for off-target, organ-specific toxicities, highlighting the need for continuous organ assessments.
展开▼
